A new study published in the journal Arthritis and Rheumatology found that minority of patients with new-onset inflammatory back pain progress to spondyloarthritis, while many resolves. Patients with new-onset inflammatory back pain have just a 30% chance of developing spondyloarthritis during the next 10 years, and a 43% probability of back pain resolution.
“[Inflammatory back pain] is commonly considered a sine qua non of spondyloarthritis (SpA), and its presence is considered an indication to refer patients to appropriate specialists for further evaluation,” Runsheng Wang, of the Columbia University College of Physicians and Surgeons, in New York, and colleagues wrote.
“Although several studies have reported the clinical evolution of patients with possible [ankylosing spondylitis] or undifferentiated SpA, no studies have specifically examined the long-term outcomes of patients with [inflammatory back pain] who do not necessarily have other SpA features,” they added.
To determine the 10-year outcomes of patients (n= 5,304; Age 16–35 years) with inflammatory back pain, as well as the predictors of SpA development, the researchers conducted a retrospective longitudinal study using data from the Rochester Epidemiology Project, a longstanding medical record-linkage system of the complete population of Olmsted County, Minnesota. The researchers identified 124 patients with inflammatory back pain.
The researchers performed medical record reviews on these patients, collecting clinical, laboratory and imaging data related to SpA, and followed their outcomes to July 2016. They then used survival analysis to evaluate their progression to either SpA, resolution of back pain or another, non-SpA diagnosis. Recursive partitioning was used to determine SpA predictors.
According to the researchers, among the 124 patients with inflammatory back pain, 39 developed SpA, while 58 experienced resolution, after a median follow-up of 13.2 years. Over a 10-year period, the probability of developing SpA was 30%, compared to a 43% probability of resolution. In addition, the most significant predictors of SpA development from inflammatory back pain were uveitis, male sex and family history of SpA.
“Our findings indicate that while [inflammatory back pain] can be a precursor of SpA, the presence of [inflammatory back pain] is not a predestination to SpA,” Wang and colleagues wrote.
“[Inflammatory back pain] is more accurately considered a symptom complex of a specific type of arthralgia that may or may not be associated with SpA and may be self-limited. Therefore, caution should be taken to not over-interpret the implications of [inflammatory back pain] for diagnosis and seek objective findings and other aspects of the medical history when counseling patients regarding their prognosis for progression to SpA.”